Adage Capital Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History

Adage Capital Partners’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-920,000	Closed	-$95.2M	–	928
2022 Q4	$95.2M	Buy	920,000 +70,000	+8%	+$6.57M	0.23%	109
2022 Q3	$72.1M	Sell	850,000 -525,000	-38%	-$46.7M	0.18%	134
2022 Q2	$114M	Sell	1,375,000 -100,000	-7%	-$7.96M	0.26%	79
2022 Q1	$114M	Sell	1,475,000 -390,000	-21%	-$32.6M	0.22%	99
2021 Q4	$165M	Buy	1,865,000 +1,470,498	+373%	+$121M	0.3%	67
2021 Q3	$30.5M	Buy	+394,502	New	+$31.1M	0.06%	329
2020 Q4	–	Sell	-484,000	Closed	-$36.8M	–	817
2020 Q3	$36.8M	Sell	484,000 -410,000	-46%	-$41.5M	0.09%	232
2020 Q2	$110M	Buy	894,000 +559,124	+167%	+$55.6M	0.28%	77
2020 Q1	$28.3M	Buy	+334,876	New	+$28.9M	0.08%	253
2019 Q2	–	Sell	-84,000	Closed	-$7.46M	–	713
2019 Q1	$7.46M	Buy	+84,000	New	+$7.79M	0.02%	566
2017 Q3	–	Sell	-673,000	Closed	-$61.1M	–	714
2017 Q2	$61.1M	Hold	673,000	–	–	0.15%	191
2017 Q1	$59.1M	Buy	673,000 +3,000	+0.4%	+$267K	0.15%	195
2016 Q4	$55.5M	Buy	670,000 +45,000	+7%	+$3.87M	0.15%	186
2016 Q3	$57.8M	Sell	625,000 -375,000	-38%	-$35.3M	0.16%	166
2016 Q2	$77.8M	Sell	1,000,000 -52,900	-5%	-$4.5M	0.21%	131
2016 Q1	$86.8M	Buy	1,052,900 +800,000	+316%	+$65.1M	0.24%	121
2015 Q4	$26.5M	Sell	252,900 -124,000	-33%	-$12.9M	0.07%	316
2015 Q3	$39.7M	Sell	376,900 -50,000	-12%	-$6.68M	0.11%	238
2015 Q2	$58.4M	Buy	426,900 +239,000	+127%	+$29.6M	0.15%	200
2015 Q1	$23.4M	Buy	+187,900	New	+$19.9M	0.06%	388

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Adage Capital Partners's BMRN Position: Q1 2023 in Review

Adage Capital Partners sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2023, closing a stake of 920,000 shares — an estimated $95.2M sold.

Adage Capital Partners first reported a position in BMRN in Q1 2015 and held it in 20 quarters. The position peaked at $165M in Q4 2021. 552 funds tracked by Wall St. Rank hold BMRN as of Q1 2023.

Adage Capital Partners reported no remaining BioMarin Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Adage Capital Partners sold 920,000 BioMarin Pharmaceuticals shares in Q1 2023, an estimated $95.2M.
Adage Capital Partners first reported a position in BioMarin Pharmaceuticals in Q1 2015 and held it in 20 quarters.
Adage Capital Partners's BioMarin Pharmaceuticals position peaked at $165M in Q4 2021.
552 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2023.

Based on Adage Capital Partners's 13F filing for Q1 2023, filed 15 May 2023.